Gene · 143384
CACUL1: CDK2 associated cullin domain 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CACUL1: CDK2 associated cullin domain 1. Genes, record 143384. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/143384
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q86Y37 | CDK2-associated and cullin domain-containing protein 1 | 369 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents9
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2025024198 A | 2025-02-19 | 9879 | Q86Y37 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 13466 | Q86Y37 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 116437 | Q86Y37 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 1515 | Q86Y37 | Espacenet |
| US 9827332 B2 | 2017-11-28 | 9879 | Q86Y37 | Espacenet |
| JP 2017121243 A | 2017-07-13 | 53847 | Q86Y37 | Espacenet |
| KR 1020170045539 A | 2017-04-27 | 8 | Q86Y37 | Espacenet |
| US 9254311 B2 | 2016-02-09 | 9879 | Q86Y37 | Espacenet |
| JP 2015513912 A | 2015-05-18 | 53847 | Q86Y37 | Espacenet |
Drugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants2,498
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CACUL1 papers | Newest fiscal year |
|---|---|---|---|
| P30CA021765 | Cancer Center Support Grant (CCSG) | 35 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 27 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 23 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 15 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 14 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 11 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 9 | 2025 |
| R01CA240981 | Harnessing E3 Ligases for Cancer Therapy | 9 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 8 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 8 | 2025 |
1 to 10 of 2,498Source NIH's project files
See all 2,498 nih grantsPapers3,620
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MLN4924 suppresses kidney renal clear cell carcinoma progression through coordinated inhibition of Cullin1 neddylation and PSMB10-associated NF-κB inflammatory signaling. | Inflamm Res | 2026 | 42802181 | PubTator, text mining | PubMed |
| L013 promotes NRF2 degradation in NRFA-subtype esophageal squamous cell carcinoma. | Cell Rep Med | 2026 | 42727581 | PubTator, text mining | PubMed |
| Neddylation as a molecular integrator of metabolic dysfunction and endothelial dysfunction in type 2 diabetes. | Acta Pharmacol Sin | 2026 | 42637928 | PubTator, text mining | PubMed |
| Neddylation-dependent RAB40-Cullin5 E3 ligase complex controls ubiquitin-mediated proteasomal degradation of DNAJC13. | BBA Adv | 2026 | 42602476 | PubTator, text mining | PubMed |
| Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer. | J Med Chem | 2026 | 42593931 | PubTator, text mining | PubMed |
| Evidence that S-phase kinase associated protein 2 (SKP2) is ubiquitinated and degraded via a Rho-related BTB domain containing 1 (RhoBTB1) and Cullin-3 mechanism in placenta. | Physiol Rep | 2026 | 42552612 | PubTator, text mining | PubMed |
| CACUL1 promotes hepatocellular carcinoma progression through enhanced tumor cell proliferation and macrophage-mediated immune suppression. | Front Immunol | 2026 | 42535029 | PubTator, text mining | PubMed |
| Genome-Wide Characterization of the F-Box Gene Family in Cardamine hupingshanensis and Functional Analysis of ChFBX171. | Biology (Basel) | 2026 | 42450551 | PubTator, text mining | PubMed |
| E3 ligase LMO7 promotes ALKBH2 ubiquitination to sensitize MGMT-deficient glioblastoma to temozolomide. | Cell Death Dis | 2026 | 42380110 | PubTator, text mining | PubMed |
| Native Mass Spectrometry Analysis of Cullin-RING Ubiquitin E3 Ligase Complexes in the Context of Targeted Protein Degradation. | Anal Chem | 2026 | 42378227 | PubTator, text mining | PubMed |
1 to 10 of 3,620
See all 3,620 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/143384
GET https://conductscience.org/api/genes/v1/143384/grants?page=2